The expression of RELN decreased in breast cancer, colorectal cancer and pancreatic cancer, but increased in retinoblastoma, myeloma and prostate cancer (Ndoye et al., 2021; Biamonte et al., 2021; Seigel et al., 2007; Qin et al., 2017). This evidence concerns the gene RELN and familial pancreatic carcinoma.